Hormone Therapy Timing & Heart Risk
study3_post02  |  image: study3_post02_clinical.png
------------------------------------------------------------------------

ON THE IMAGE
919,614 — women in a national register study of contemporary hormone therapy

CAPTION
Modern prescribing data at national scale.

A Swedish register study followed 919,614 women aged 50–58, including 77,512 who started hormone therapy. Transdermal estrogen showed no significant increase in cardiovascular risk. Oral continuous combined therapy was linked to a modest increase in ischemic heart disease.

Over the study period, cardiovascular incidence fell by more than half as prescribing shifted toward transdermal options.

Questions about what this means for you? Call [Practice Name] at [Phone] or book at [Booking Link].

Educational content, not medical advice — individual results and risks vary.

HASHTAGS
#menopause #womenshealth #hearthealth #hormonetherapy #midlifewomen

SUPPORTING EVIDENCE
Observational studies section: 919,614 women, 77,512 initiated HRT; transdermal not associated with significant increase in CVD risk.
